Experimental cancer drug combo trial halted early

NCT ID NCT03426371

Terminated Disease control Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tested a drug called A140 (similar to cetuximab) combined with chemotherapy (mFOLFOX6) as a first treatment for people with a specific type of advanced colorectal cancer (RAS wild-type). The study planned to enroll 570 people in China but was terminated early with only 52 participants. The goal was to see if the combination slowed cancer growth and improved survival. Because the trial stopped early, the results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A140 (a biosimilar to cetuximab) plus chemotherapy (mFOLFOX6)
What this could lead to: If successful, this could provide a new treatment option for people with a specific type of advanced colorectal cancer.
What could go wrong: The trial was terminated early with only 52 participants instead of the planned 570, so results are very limited and may not be reliable. It is unclear if A140 works better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

307 Hospital of PLA

Beijing, Beijing Municipality, 100071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.